特定混合益生菌或能改善多发性硬化
  • 口服多菌益生菌(Vivomixx)可改善慢性进展型多发性硬化小鼠的运动功能;
  • Vivomixx可增加拟杆菌门、放线菌门、柔膜菌门和TM7的丰度,降低厚壁菌门丰度;
  • Vivomixx减少大脑中的小胶质细胞和星形胶质细胞的增生以及白细胞浸润、增加特定Breg细胞亚群,促进脊髓内的抗炎作用;
  • Vivomixx增加小鼠血浆中的丁酸和乙酸含量,调节外周免疫系统;
  • 调控特定菌群、平衡菌群与宿主免疫系统双向作用,是治疗多发性硬化的潜在方法。
主编推荐语
mildbreeze
Gut Microbes发表的一项研究,在进展型多发性硬化小鼠模型中,分析了一种多菌株益生菌Vivomixx(包含副干酪乳杆菌DSM 24734、植物乳杆菌DSM 24730、嗜酸乳杆菌DSM 24735、德氏乳杆菌保加利亚亚种DSM 24734、长双歧杆菌DSM 24736、婴儿双歧杆菌DSM 24737、短双歧杆菌DSM 24732、嗜热链球菌DSM 24731)对肠道菌群以及中枢和外周免疫反应的影响。
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!
图片
Gut Microbes [IF:10.245]

How oral probiotics affect the severity of an experimental model of progressive multiple sclerosis? Bringing commensal bacteria into the neurodegenerative process

口服益生菌如何影响进展型多发性硬化实验模型的严重程度?将共生细菌带入神经退行性过程

10.1080/19490976.2020.1813532

2020-09-08, Article

Abstract & Authors:展开

Abstract:收起
A growing number of studies support that the bidirectional interactions between the gut microbiota, the immune system and the CNS are relevant for the pathophysiology of MS. Several studies have reported alterations in the gut microbiome of MS patients. In addition, a variety of studies in animal models of MS have suggested that specific members of the gut commensal microbiota can exacerbate or ameliorate neuroinflammation. Probiotics represent oral nontoxic immunomodulatory agents that would exert benefits when using in combination with current MS therapy. Here we investigate the effect of Vivomixx on the gut microbiome and central and peripheral immune responses in a murine model of primary progressive MS. Vivomixx administration was associated with increased abundance of many taxa such as Bacteroidetes, Actinobacteria, Tenericutes and TM7. This was accompanied by a clear improvement of the motor disability of Theiler’s virus infected mice; in the CNS Vivomixx reduced microgliosis, astrogliosis and leukocyte infiltration. Notably, the presence of Breg cells (CD19+CD5+CD1dhigh) in the CNS was enhanced by Vivomixx, and while spinal cord gene expression of IL-1β and IL-6 was diminished, the probiotic promoted IL-10 gene expression. One of the most significant findings was the increased plasma levels of butyrate and acetate levels in TMEV-mice that received Vivomixx. Peripheral immunological changes were subtle but interestingly, the probiotic restricted IL-17 production by Th17-polarized CD4+ T-cells purified from the mesenteric lymph nodes of Theiler’s virus infected mice. Our data reinforce the beneficial effects of oral probiotics that would be coadjuvant treatments to current MS therapies.

First Authors:
Leyre Mestre,Francisco J Carrillo-Salinas

Correspondence Authors:
Leyre Mestre,Carmen Guaza

All Authors:
Leyre Mestre,Francisco J Carrillo-Salinas,Ana Feliú,Miriam Mecha,Graciela Alonso,Carmen Espejo,Laura Calvo-Barreiro,José L Luque-García,Héctor Estevez,Luisa María Villar,Carmen Guaza

评论